JP2007530550A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530550A5
JP2007530550A5 JP2007505054A JP2007505054A JP2007530550A5 JP 2007530550 A5 JP2007530550 A5 JP 2007530550A5 JP 2007505054 A JP2007505054 A JP 2007505054A JP 2007505054 A JP2007505054 A JP 2007505054A JP 2007530550 A5 JP2007530550 A5 JP 2007530550A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
alkenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009301 external-priority patent/WO2005097806A1/en
Publication of JP2007530550A publication Critical patent/JP2007530550A/ja
Publication of JP2007530550A5 publication Critical patent/JP2007530550A5/ja
Pending legal-status Critical Current

Links

JP2007505054A 2004-03-26 2005-03-17 異脂肪血症を治療するための化合物および方法 Pending JP2007530550A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22
PCT/US2005/009301 WO2005097806A1 (en) 2004-03-26 2005-03-17 Compounds and methods for treating dyslipidemia

Publications (2)

Publication Number Publication Date
JP2007530550A JP2007530550A (ja) 2007-11-01
JP2007530550A5 true JP2007530550A5 (el) 2008-04-24

Family

ID=34963426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505054A Pending JP2007530550A (ja) 2004-03-26 2005-03-17 異脂肪血症を治療するための化合物および方法

Country Status (21)

Country Link
US (2) US20070208003A1 (el)
EP (2) EP1732933B1 (el)
JP (1) JP2007530550A (el)
KR (1) KR20070007112A (el)
AT (2) ATE402180T1 (el)
AU (1) AU2005230915A1 (el)
BR (1) BRPI0508966A (el)
CA (1) CA2557010A1 (el)
CY (1) CY1110398T1 (el)
DE (2) DE602005014955D1 (el)
DK (1) DK1732933T3 (el)
EA (1) EA200601785A1 (el)
EC (1) ECSP066886A (el)
ES (2) ES2326326T3 (el)
IL (1) IL177962A0 (el)
MA (1) MA28550B1 (el)
NO (1) NO20064763L (el)
PL (1) PL1732933T3 (el)
PT (1) PT1732933E (el)
SI (1) SI1732933T1 (el)
WO (2) WO2005097806A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
US20070208003A1 (en) * 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
KR20070041452A (ko) 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
US8759365B2 (en) * 2007-12-03 2014-06-24 Novartis Ag Organic compounds
AU2008335788B2 (en) * 2007-12-12 2012-11-29 Amgen Inc. Glycine transporter-1 inhibitors
JP5586585B2 (ja) * 2009-03-27 2014-09-10 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
PE20120403A1 (es) 2009-05-15 2012-05-03 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona
CA2761853A1 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
EP2538947B1 (en) * 2010-02-24 2016-08-17 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants
EP2566505B1 (en) 2010-05-06 2019-10-16 Alphacore Pharma LLC Delivery of cholesteryl ester to steroidogenic tissues
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
WO2013080999A1 (ja) 2011-11-29 2013-06-06 興和株式会社 ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) * 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
AU6279598A (en) * 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
WO2003057671A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Compose biaryle et son utilisation
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
CN1289467C (zh) 2002-08-30 2006-12-13 日本烟草产业株式会社 二苄胺化合物及其药物用途
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
US20070208003A1 (en) 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법

Similar Documents

Publication Publication Date Title
JP2007530550A5 (el)
US11648244B2 (en) Methods for the treatment of abnormal involuntary movement disorders
AU2016276806B2 (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
AU2011328203B2 (en) 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2799640C (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
CN105073738B (zh) 作为钠通道调节剂的喹啉及喹喔啉酰胺类
US8034826B2 (en) Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors
RU2240322C2 (ru) Производные нафтиридина и содержащая их фармацевтическая композиция
KR20010050223A (ko) Ｃｒｆ 길항제 및 관련 조성물의 용도
JP2005533868A5 (el)
CN105130957A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
JP2019069966A (ja) Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
CN103717574A (zh) 用于抑制nampt的新化合物和组合物
KR20060041254A (ko) 퀴놀론 유도체 또는 그의 염
CN101089000B (zh) 螺环哌嗪季铵盐类化合物及其制备方法和应用
WO2017176962A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP1145714A1 (en) Drugs
US7176313B2 (en) Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient
KR20110021946A (ko) 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도
KR20080083706A (ko) 헤테로이환 아마이드 유도체
KR20110010725A (ko) 무스카린성 수용체 길항제 및 β２­아드레날린수용체 효능제를 포함하는 제약 생성물
US8481561B2 (en) Classes of GABAA/BZR ligands
JP4853824B2 (ja) キノロン誘導体を有効成分とする医薬組成物
US11738008B2 (en) N-methyl-D-aspartic acid receptor modulators
TW201726617A (zh) Ｓｉｒｔ１受體的四氫咔唑抑制劑